Stem cell transplantation in rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunology
• Hematology

Background:

• High-dose chemotherapy and stem cell transplantation (SCT) showed early promise for severe rheumatoid arthritis (RA) based on animal studies and case reports.
• Early clinical studies (Phase I/II) confirmed the feasibility, safety, and efficacy of autologous SCT for RA, demonstrating profound responses.

Purpose of the Study:

• To evaluate the therapeutic potential and limitations of autologous and allogeneic stem cell transplantation (SCT) in severe rheumatoid arthritis (RA).
• To understand the role of SCT in RA pathophysiology and its place in modern treatment paradigms.

Main Methods:

• Review of Phase I, II, and III clinical studies on autologous SCT for RA.
• Analysis of outcomes including disease response, need for additional therapies, and conditioning regimen effects.
• Consideration of allogeneic and syngeneic SCT cases and their associated challenges.

Main Results:

• Autologous SCT can achieve significant responses, but sustained disease control often necessitates reintroduction of disease-modifying agents.
• Dose escalation of conditioning regimens and post-transplant therapies like rituximab improved responses.
• Phase III study recruitment was hampered by the rise of biological anti-rheumatic agents, restricting autologous SCT to refractory cases.
• Allogeneic and syngeneic SCT show potential for cure in some cases but face significant logistical and toxicity hurdles.

Conclusions:

• Autologous SCT is a limited therapeutic option for rare RA patients resistant to conventional and biological treatments.
• While SCT offers insights into RA pathophysiology, its widespread application is limited by efficacy and safety concerns.
• SCT remains a niche treatment for severe, refractory RA, requiring careful patient selection.